ArticleRisk management and healthcare policy2024
Extended-Spectrum β-Lactamase-Producing
Article in Risk management and healthcare policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Antimicrobial resistance analysis of Klebsiella pneumoniae bloodstream infections based on a random forest algorithm: a longitudinal study based on data from tertiary hospitals in China from 2012 to 2023.International health · 2026Article
- Hospital Cost Components and Predictors inTropical medicine and infectious disease · 2026Article
- Environmental dissemination of multidrug-resistant Escherichia coli across one health interfaces in Mymensingh, Bangladesh.npj antimicrobials and resistance · 2026Article
- Elevated D-dimer is independently associated with in-hospital mortality in patients withFrontiers in cellular and infection microbiology · 2026Article
- The Association Between C-Reactive Protein-to-Albumin Ratio and in-Hospital Mortality in Patients withJournal of inflammation research · 2026Article
- Multidrug-resistantmSystems · 2025Article
- Direct economic costs related to antimicrobial resistance in bloodstream infections isolated from newborns in a perinatal hospital in Peru.International health · 2025Article
- Economic and Disease Burden Associated with Invasive Escherichia coli Disease in the United States.Infectious diseases and therapy · 2025Article
- The burden of infections caused by Metallo-Beta-Lactamase-Producing Enterobacterales in Italy: epidemiology, outcomes, and management.Le infezioni in medicina · 2025Review
- Association Between Red Cell Distribution Width and Mortality in Patients withInfection and drug resistance · 2025Article
- Genetic Analyses of Rare ESBL ST628Microorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although Extended-spectrum β-lactamase-producing Data Source and Methods: We performed a retrospective analysis of inpatients diagnosed with Results: We found 166 ESBL-EC/KP BSI patients (52.2% of the total examined 318 patients). Post-PSM analysis revealed that ESBL-producing EC/KP will reduce the effectiveness of empirical medication by 19.8%, extend the total length of hospitalization by an average of 3 days, and increase the patient's financial burden by US$2047. No significant disparity was found in overall mortality and mean DALYs between the groups. Mediation analysis showed that the link between ESBL and hospital costs is predominantly, if not entirely, influenced by the appropriateness of empirical antibiotic treatment and length of hospital stay. Conclusion: Patients with BSI due to ESBL-producing ESBL-EK incur higher costs compared to those with non-ESBL-EK BSI. This cost disparity is rooted in varying rates of effective empirical antimicrobial therapy and differences in hospital stay durations. A nuanced approach, incorporating a thorough understanding of regional epidemiological trends and judicious antibiotic use, is crucial for mitigating the financial impact on patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.